A Phase 2B, Multi-center, Randomized, Double-Blind, Vehicle Controlled Study of the Effectiveness and Safety of SD-101 Cream in Subjects With Epidermolysis Bullosa

The purpose of this study is to assess whether SD-101 cream (3% or 6%) is effective in treating the lesions in subjects with Simplex, Recessive Dystrophic, or Junctional Epidermolysis Bullosa.

Stanford is now accepting new patients for this trial. Please contact Emily Gorell at 650-721-7166 for more information.

Intervention(s):

  • drug : 3% SD-101 dermal cream
  • drug : Vehicle (0% SD-101)
  • drug : 6% SD-101 dermal cream

Phase: Phase 2

Eligibility

Ages Eligible For Study:

6 Months - N/A

Inclusion Criteria

- Informed Consent form signed by the subject or the subject's legal representative; if the subject is under the age of 18 but capable of providing assent, signed assent from the subject. - Subject (or caretaker) must be willing to comply with all protocol requirements. - Diagnosis of Simplex, Recessive Dystrophic, or Junctional non-Herlitz EB. - Subjects must be 6 months of age and older. - Subjects must have 1 target wound within a prespecified size range at study entry - Target wound must be of at least a certain age

External Links

Explore related trials

Contact information

Primary Contact:

Emily Gorell 650-721-7166

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: